SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure
- PMID: 32640243
- DOI: 10.1016/j.cmet.2020.06.014
SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure
Abstract
Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. (2020) reported the first human study investigating the diuretic effect of empagliflozin.
Copyright © 2020. Published by Elsevier Inc.
Comment on
-
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.Circulation. 2020 Sep 15;142(11):1028-1039. doi: 10.1161/CIRCULATIONAHA.120.045691. Epub 2020 May 15. Circulation. 2020. PMID: 32410463 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical